Physician profile
Robert S Friedman
NPI 1750327177
$12,094.11
in general payments reported to CMS, 2019-2025
31 companies · $2,493 in 2025
The $2,493 reported for 2025 was more than what 90% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,425 · 2020: $881 · 2021: $1,594 · 2022: $1,255 · 2023: $2,039 · 2024: $2,407 · 2025: $2,493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,113 · Travel and Lodging: $826.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,113.12 |
| Travel and Lodging | $825.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,114.67 | 2022-2025 | |
| Alcon Vision LLC | $1,995.42 | 2019-2025 | Hydrus Microstent, Clareon, Clareon Panoptix Pro |
| Sight Sciences, INC. | $1,622.39 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
| Allergan, INC. | $1,417.51 | 2019-2022 | |
| Biotissue Holdings INC. | $1,173.20 | 2024 | |
| Ocular Therapeutix, INC. | $513.61 | 2019-2025 | Dextenza |
| Johnson & Johnson Surgical Vision, INC. | $374.20 | 2021-2023 | Tecnis Iol |
| Ivantis, INC | $363.31 | 2021 | |
| Aerie Pharmaceuticals, INC. | $336.15 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $278.19 | 2019-2025 | |
| Rayner Intraocular Lenses Limited | $236.05 | 2022-2024 | Omidria, Omidria, Rayone Aspheric |
| Horizon Therapeutics Plc | $234.31 | 2021-2023 | Tepezza |
| Nova Eye, INC. | $165.81 | 2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $165.76 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $148.70 | 2019-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $144.92 | 2019-2025 | Idosetr |
| Omeros Corporation | $125.00 | 2019 | |
| Genentech USA, INC. | $113.37 | 2019 | |
| Rxsight INC | $87.92 | 2021 | |
| Kala Pharmaceuticals, INC. | $74.57 | 2019-2022 | |
| Carl Zeiss Meditec, INC. | $64.71 | 2019 | |
| Dompe US, INC. | $59.28 | 2021-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $54.44 | 2022-2024 | Miebo, Xiidra |
| Astellas Pharma US INC | $46.89 | 2023 | |
| Oyster Point Pharma, INC. | $43.81 | 2025 | Tyrvaya |
| Harrow Eye, LLC | $38.57 | 2024 | Vevye |
| Shire North American Group INC | $26.91 | 2019 | |
| Mallinckrodt Hospital Products INC. | $21.08 | 2020 | |
| Johnson & Johnson Vision Care, INC. | $20.26 | 2025 | |
| New World Medical,INC. | $17.13 | 2023 | |
| Eyevance Pharmaceuticals LLC | $15.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Friedman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.